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A B S T R A C TObjective: Major depressive disorder (MDD) is often underdiagnosed,
undertreated, and associated with negative health outcomes. The
current study examined the prevalence of MDD signs and symptoms
in Brazil, including awareness, diagnosis, treatment, and the associa-
tion of MDD with health outcomes. Methods: Data were collected
from the 2011 National Health and Wellness Survey in Brazil (N ¼
12,000). Excluding those with bipolar disorder, respondents who met
Patient Health Questionnaire-9 criteria for MDD (n ¼ 1105) were
compared with those not qualifying as having MDD or any depressive
symptoms (n ¼ 8684), analyzing separately those currently taking (n ¼
184) or not taking (n ¼ 155) prescription medication for depression.
Sociodemographics and health status, symptoms, experience of
depression, diagnosis, MDD severity, pharmacotherapy, productivity
impairment (Work Productivity and Activity Impairment question-
naire), health status (Short-Form 12, version 2), and health care
resource use were measured. Results were weighted and projected
to the Brazil adult population. Differences were measured with
column proportion and mean tests for categorical and continuousnt matter Copyright & 2012, International Society
r Inc.
.1016/j.vhri.2012.09.011
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ondence to: Amir Goren, Kantar Health, 11 Madisonoutcomes, respectively. Results: MDD prevalence was 10.2%, with
only 28.1% of the individuals with MDD diagnosed and 15.6% currently
using prescription medication for depression. Males were especially
likely to be unaware of MDD. Compared with non-MDD controls,
patients with MDD (treated or untreated) reported significantly greater
overall work impairment, worse mental and physical health status,
and greater health care resource utilization (all Po 0.05). There was a
trend for worsening health outcomes with increasing MDD severity.
Conclusions: These findings suggest that Brazilians may be under-
diagnosed and undertreated for MDD. Individuals with MDD reported
substantially poorer health outcomes, suggesting the need to increase
MDD awareness, especially among males, and provide better access to
treatment.
Keywords: Brazil, depression, health-related quality of life, major
depressive disorder, prevalence, resource use, treatment, work
productivity.
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Outcomes Research (ISPOR). Published by Elsevier Inc.Introduction
Major depressive disorder (MDD) is characterized essentially by
‘‘depressed mood’’ and ‘‘loss of interest or pleasure in nearly all
activities’’ according to the Diagnostic and Statistical Manual of
Mental Disorders IV [1]. MDD is a common mental condition
associated with substantial morbidity and economic burden [2].
The World Health Organization ranks depression as the largest
contributor to years lost to disability and the fourth largest
contributor to disability-adjusted life-years [2]. Other signs and
symptoms include feelings of guilt, anxiety, fatigue, sleep dis-
turbance, and cognitive and sexual dysfunction [3].
MDD is common in Brazil, with recent estimates of 1-year
prevalence ranging from 7.1% to 10.0% [4–6]. Yet, evidence
suggests that Brazilians with MDD do not often seek mental
health treatment and may incur substantial costs because ofother forms of health care service utilization and work loss [4–6].
Andrade et al. found that 46.7% of S ~ao Paulo city residents with
mood disorder reported utilizing general medical care in the past
month and 23.2% utilized specialty medical care in the past month.
In a later analysis, however, Andrade et al. found that only 7.7% of
S ~ao Paulo residents with mental disorder sought health care
treatment for their mental condition in the preceding year. In the
United States, it is estimated that only 33.9% of the individuals with
MDD are treated pharmaceutically [7]. It is unclear to what extent
Brazilians are aware of the signs or symptoms consistent with MDD
and to what extent they are diagnosed and treated.
MDD may also affect health-related quality of life (QOL). As
Herrman et al. [8] found, Brazilian outpatients with high depres-
sion severity scores on the Center for Epidemiologic Studies
Depression Scale were less likely to report good to excellent
health, to be satisfied with their health, or to report good to veryfor Pharmacoeconomics and Outcomes Research (ISPOR).
o conflicts of interest with regard to the content of this article.
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Moreover, Guajardo et al. [9] showed that outpatients with the
core symptoms of MDD (loss of interest and depressed mood)
exhibited significantly lower health-related QOL scores on all
domains of the Short Form-36. Similar results were reported by
Rocha and Fleck [10], administering the World Health Organiza-
tion QOL-BREF instrument, among a sample of 119 community-
dwelling adults and 122 tertiary hospital patients.
Brazil is a large nation, with diverse cultural and socio-
economic circumstances, limiting the generalizability of burden
of illness studies employing outpatient samples (of which there
are several examples) [8,9,11–14]. Other studies measured the
effect of MDD in unique subpopulations, such as caretakers [15],
health service workers [16,17], or the elderly [18–20]. Still other
studies measured the effect of MDD in respondents with comor-
bidities known to occur with depressive symptoms [21–23].
The effect of MDD in particular subpopulations or among
respondents with particular comorbidities cannot be assumed
equivalent to its effect in the general population or among
respondents without those comorbidities. Similarly, treatment
rates of MDD in primary care–based settings may overestimate
the true rates present in the general community, in which
respondents may not readily seek health care services. Few, if
any, studies have assessed the extent to which Brazilian residents
are aware that they exhibit signs or symptoms consistent with
MDD or how frequently MDD cases are diagnosed.
As such, population-based comparisons of respondents with
and without MDD are needed to describe the burden of MDD in
Brazil. Moreover, epidemiological data are needed to elucidate
the extent to which Brazilian residents exhibit symptoms of
MDD, are aware of symptoms and signs of MDD, and are
diagnosed or treated for their condition.
The objective of the current study was to measure the prevalence
of signs and symptoms consistent with MDD and to determine the
extent to which respondents are aware of their condition and are
diagnosed and treated for it, in a population-based sample in Brazil.
Furthermore, the study sought to determine the association between
MDD and health-related QOL, work productivity, and health care
utilization by comparing respondents treated or untreated for MDD
with those not experiencing any MDD symptoms, as well as
examining MDD and outcomes at differing levels of severity.Methods
Sample and Procedure
Data were collected from the 2011 National Health and Wellness
Survey in Brazil, a cross-sectional survey of adults aged 18 years
or older (Kantar Health, New York, NY) fielded initially in the
United States in 1998 and now expanded to 10 countries. Initial
translation of the English survey to Portuguese, excluding instru-
ments listed below that were explicitly validated in Portuguese by
the authors, was handled by Transperfect (http://www.transper
fect.com), which is certified to ISO 9001:2008 and EN 15038:2006
standards. Review of the translation was then conducted by
Absolute Translations (http://www.absolutetranslations.com),
which is certified to ISO 9001 standards. Invitations to participate
were sent to members of the Lightspeed Research Internet panel
via e-mail, and the survey was administered online, with some
respondents (especially those aged 65þ years) using computer-
assisted Web interviews, in select facilities or participants’ homes
for those unable to travel. By using this approach, gender-matched
interviewers were assigned to read and input the responses from
these participants into the Internet-based survey. A stratified,
random sampling procedure (for all participants) was implemen
ted according to gender and age (based on the InternationalDatabase of the U.S. Census [http://www.census.gov/population/
international/data/idb/informationGateway.php]) for the final
sample to be representative of the general Brazilian population.
All participants gave explicit informed consent, and second-
ary consent forms were completed to allow for interviewer
administration of computer-assisted Web interviews. Institu-
tional review board approval was granted by Essex Institutional
Review Board (Lebanon, NJ). A total of 12,000 respondents (1,364
via computer-assisted Web interviews and 10,636 online) gave their
informed consent, met the inclusion criteria (aged 18 years or older),
and completed the survey instrument (response rate of 4.6% for the
232,063 invited to complete the survey online). Respondents with
bipolar disorder, either based on screening criteria from the Mood
Disorder Questionnaire [24] or self-reported experience of bipolar
disorder, were excluded from analysis. Respondents were included
for analysis if they either experienced symptoms of MDD or if they
did not report or experience any depression symptoms. A total of
n ¼ 9789 respondents were included for analysis (see Fig. 1).
Measures
Major depressive disorder
Respondents were asked within the National Health and Wellness
Survey to report whether they experienced depression in the past 12
months, were diagnosed with depression by a physician, and were
currently taking a prescription medication for their depression.
The Patient Health Questionnaire 9 (PHQ-9) was used to
classify respondents as having MDD or MDD symptoms, or both,
and to classify the severity of depression (moderate, moderately
severe, or severe) [25,26]. The PHQ-9 is a nine-item screening
questionnaire assessing the frequency of reported symptoms of
MDD (each rated on a scale of 0 ¼ ‘‘not at all’’ to 3 ¼ ‘‘nearly every
day’’), based on the Diagnostic and Statistical Manual of Mental Disorders
IV criteria for diagnosing MDD in patients with mental illness.
Respondents are identified as having MDD if they select a frequency
of ‘‘more than half the days’’ and above (in the last 2 weeks) for five
or more of the items, with the caveat that they must select this
frequency for at least one of the first two items (‘‘little interest’’ and
‘‘feeling down’’), and the last item (‘‘thoughts of suicide/self-harm’’) is
counted even if a frequency of ‘‘several days’’ is selected. The level of
depression severity was assessed according to the following total
scores: 0 to 4 ¼ ‘‘minimal,’’ 5 to 9 ¼ ‘‘mild,’’ 10 to 14 ¼ ‘‘moderate,’’ 15
to 19 ¼ ‘‘moderately severe,’’ and 20 to 27 ¼ ‘‘severe.’’
Demographics
Gender (male or female), age (years), marital status (married,
single and never married, separated, or divorced), employment
status (full time, part time, or self-employed), income (rR$ 2000),
educational attainment (some college or more), and socioeco-
nomic status (A1–A2 [upper class], B1–B2 [middle class], C1 [lower
middle class], C2 [skilled working class], D [lower working class],
and E [lowest income earners]) were assessed, with C2, D, and E
grouped for analysis to reflect the broader lower class, as
differentiated from C1 (a growing middle-class segment) and
the other classes [27]. These classifications were developed by
the National Readership Survey to gather statistics on media
audiences (television, radio), and as a way to classify social
classes for media outlets. Regional information (north, northeast,
center west, southeast, south, or unspecified) was also collected.
Health characteristics
Body mass index (obese: Z30 kg/m2), tobacco smoking status
(current smoker), alcohol usage, mean number of days partici-
pants exercised in the past month, Charlson comorbidity index
scores (0, 1, 2, or 3 and above, indicating increasing degree of
comorbid mortality risk) [28], self-reported depression severity
Fig. 1 – Inclusion criteria and prevalence estimates.
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prescription medication, symptoms prompting doctor visits, and
depression-diagnosing clinician were assessed.Health status
Health status was measured by using the Brazilian Portuguese
version of the Short-Form 12, version 2 (SF-12v2), a generic
instrument consisting of 12 items [29,30]. The physical compo-
nent summary and mental component summary scores, as well
as six-dimensional health state short form (derived from short-
form 36 health survey) utility index, were computed from SF-12v2
items (seven items were used to calculate six-dimensional health
state short form [derived from short-form 36 health survey]-
scores) and reported in the current findings [29]. Higher physical
component summary and mental component summary scores
represent better health status. The six-dimensional health state
short form utility index varies on a theoretical scale of 0 to 1,
where 0 represents death and 1 represents perfect health.Work impairment
Work loss was captured via the Work Productivity and Activity
Impairment (WPAI) questionnaire, a validated instrument con-
taining four subscales (absenteeism, presenteeism, overall work
impairment, and activity impairment) [31]. Absenteeism repre-
sents the percentage work time missed because of health in the
past 7 days. Presenteeism represents impairment while at work
because of health in the past 7 days (measured with an 11-point
Likert-type scale). Overall work impairment represents the total
work time missed because of health in the past 7 days (absentee-
ism and presenteeism). Activity impairment represents the
percentage impairment of daily activities outside work because
of health in the past 7 days.Health care resource use
Health care utilization was measured by the self-reported num-
ber of physician visits, emergency room (ER) visits, and hospita-
lizations in the preceding 6 months.
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Analyses were conducted to determine the 12-month period
prevalence of experiencing depression and point prevalence of
MDD and MDD symptoms (see Measures). Among those who
tested positively for MDD, prevalence estimates of depression
awareness (12-month period prevalence of experiencing depres-
sion), diagnosis, treatment, and severity were calculated (see
Fig. 1). Within those groups, descriptive statistics were calculated
to fully describe the entire sample (see Tables 1–3). Frequencies
and percentages (for categorical variables) and means and SDs
(for continuous variables) were reported.
The following groups were then compared (using t tests and chi-
square tests for categorical and continuous variables, respectively).
Participants treated and not treated for MDD, versus controls
Those who were identified as MDD positive via the PHQ-9, self-
reported experiencing depression in the past 12 months, were
diagnosed with depression by a physician and either were or
were not currently taking a prescription medication were classi-
fied as being treated for MDD (n ¼ 184) or untreated for MDD
(n ¼ 155), respectively. Respondents who did not screen positively
for depressive symptoms through the PHQ-9 or self-reported
experiencing depression in the past 12 months were classified
as controls (n ¼ 8684).Table 1 – Demographics.
Nondepre
control gro
98.7 M (n ¼
%
Demographics
% Males 52.0BC
% Females 48.0
Mean age  SD (y) 41.9  16.2C
% Married 37.7
% Single, never married 35.3
% Separated 5.3
% Divorced 6.2
% Employed (full time, part time, self-employed) 64.2
% Income (rR $2000) 45.1
% College educated 21.9
Socioeconomic status
Socioeconomic group 1 (A1–A2) 5.0
Socioeconomic group 2 (B1) 9.2
Socioeconomic group 3 (B2) 14.9
Socioeconomic group 4 (C1) 20.8
Socioeconomic group 5 (C2, D, E) 50.1
Region
North 3.5
Northeast 15.8B
Center west 6.3
Southeast 59.7
South 14.4
Not specified 0.4
Notes. Nondepressed control group: No depression symptoms, no bipola
column(s) that differ significantly at Po 0.05. Statistical comparisons not
B/C. Table includes results based on weighted and projected values.
K, thousand; M, million; MDD, major depressive disorder; MDQ, Mood D
* Patients who were treated for depression with a prescription medicatiParticipants with different degrees of MDD severity
Patients with MDD were compared across levels of severity,
within both the treated and untreated groups. All results were
weighted by gender, age, and socioeconomic status (from Inter-
national Data Base of the U.S. Census Bureau and Organization
for Economic Cooperation) so that projections could be made to
the overall Brazilian population. Two-tailed significance was
determined by P values of less than 0.05.Results
Sample Descriptives
Of the total sample (n ¼ 11,548) of respondents without
bipolar disorder, 1,864 individuals (16.1%) reported symptoms
consistent with depression, of which 1,105 (59.3%) tested
positive for MDD (see Fig. 1). Among those who tested positive
for MDD, 476 (43.1%) reported experiencing depression in the
past 12 months, of whom 339 (71.2%) also reported being
diagnosed with depression by a physician. Among those diag-
nosed with depression, 184 (54.3%) reported currently taking a
prescription medication for their depression, whereas 155
(45.7%) did not.Among MDD, diagnosed with depression
ssed
up A,
Treated B, Untreated C,
8684) 2.1 M (n ¼ 184) 1.7 M (n ¼ 155)
n % n % n
51.3 M 28.5 587 K 20.1 345 K
47.4 M 71.5A 1.5 M 79.9A 1.4 M
41.7  10.8C 35.8  9.4
37.2 M 37.2 766 K 34.0 584 K
34.8 M 26.3 541 K 30.9 532 K
5.3 M 14.0A 288 K 12.3A 211 K
6.1 M 10.0 206 K 4.0 69 K
63.3 M 59.4 1.2 M 59.1 1.0 M
44.5 M 43.6 898 K 55.9 961 K
21.6 M 20.1 414 K 23.9 410 K
5.0 M 6.6 137 K 3.4 58 K
9.1 M 11.0 227 K 9.5 164 K
14.7 M 16.0 328 K 15.4 264 K
20.5 M 21.0 432 K 32.9A 565 K
49.4 M 45.4 935 K 38.8 667 K
3.4 M – 0 K – 0 K
15.6 M 6.1 125 K 12.7 218 K
6.2 M 8.0 165 K 10.7 184 K
58.9 M 55.5 1.1 M 64.4 1.1 M
14.2 M 30.4AC 626 K 12.3 210 K
341 K – 0 K – 0 K
r disorder, and no positive MDQ score. Letters indicate the subgroup
ed on this table include the following column comparisons: A/B, A/C,
isorder Questionnaire; R $, Brazilian real.
on.
Table 2 – Health characteristics.
Among MDD, diagnosed with depression
Nondepressed control group Treated Untreated
A B C
%/mean n/SD %/mean n/SD %/mean n/SD
Health status
Mean BMI 25.6 5.4 26.8 5.8 26.7 6.5
% obese (BMI Z 30) 16.0 15.5 M 25.7A 529 K 26.7A 438 K
% smoke cigarettes 18.8 18.6 M 38.0A 781 K 27.7 476 K
% drink alcohol 51.6 51.0 M 48.4 997 K 67.8AB 1.2 M
Mean days exercised in the past month 7.1B 9.4 3.4 6.1 5.2 8.6
Charlson comorbidity index scoring
0 84.3BC 83.2 M 52.1 1.1 M 58.5 1.0 M
1 10.6 10.4 M 29.5A 608 K 19.4A 333 K
2 3.7 3.6 M 11.8A 244 K 15.9A 272 K
3þ 1.5 1.5 M 6.6A 135 K 6.3A 108 K
Mean 0.3 0.8 0.8A 1.1 0.7A 1.1
Note. Nondepressed control group: No depression symptoms, no bipolar disorder, and no positive MDQ score. Letters indicate the subgroup
column(s) that differ significantly at Po 0.05. Statistical comparisons noted on this table include the following column comparisons: A/B, A/C,
B/C. Table includes results based on weighted and projected values.
BMI, body mass index; K, thousand; M, million; MDD, major depressive disorder; MDQ, Mood Disorder Questionnaire.
* Patients who were treated for depression with a prescription medication.
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(15.8%), 67 (36.4%), and 88 (47.8%) were classified as having
moderate, moderately severe, and severe MDD, respectively.Table 3 – Health outcomes for MDD vs. nondepressed controls.
Nondepre
gro
98.7 M
Work productivity
% of missed work time (absenteeism)† 5.5
Hours missed (absenteeism)† 2.7
% of impairment at work (presenteeism)† 11.2
% of overall impairment† 14.8
% of activity impairmentz 15.3
Health-related quality of life
Mental component summary (MCS) score 50.4
Physical component summary (PCS) score 50.5
Health utilities 0.770
Resource use
Traditional health care provider visits (including 0) 3.3
Median traditional health care provider visitsy 2.
ER visits (including 0) 0.4
Visited ER in past 6 mo, % (n) 17.3
Hospitalized in past 6 mo, % (n) 7.7
Notes. Nondepressed control group: No depression symptoms, no bipola
column(s) that differ significantly at Po 0.05. Statistical comparisons not
Table includes results based on weighted and projected values. Values a
ER, emergency room; K, thousand; M, million; MDD, major depressive d
* Patients who were treated for depression with a prescription medicati
† Employed full time.
z All respondents.
y Because of high values of visits for select respondents, median valuesAmong those not taking a prescription for their depression, 16
(10.3%), 63 (40.6%), and 76 (49.0%) were classified as having
moderate, moderately severe, and severe MDD, respectively.Among MDD, diagnosed with depression
ssed control
up A,
Treated B, Untreated C,
(n ¼ 8684) 2.1 M (n ¼ 184) 1.7 M (n ¼ 155)
 17.6 36.6  44.5A 12.3  22.2
 10.1 18.4  24.1A 6.0  12.0
 21.7 35.2  34.3A 37.5  29.4A
 26.1 56.7  41.6A 43.0  32.1A
 23.9 62.9  32.9A 47.5  33.7A
 9.5BC 29.9  11.7 29.5  9.5
 8.2BC 43.6  10.7 45.8  8.5
 0.1BC 0.547  0.1 0.572  0.1
 5.6 14.4  20.6A 8.4  10.5A
0 6.0 5.0
 1.5 1.8  3.7A 1.6  3.6A
(17.1 M) 53.6 (1.1 M)A 43.2 (743 K)A
(7.6 M) 23.7 (489 K)A 17.7 (305 K)A
r disorder, and no positive MDQ score. Letters indicate the subgroup
ed on this table include the following column comparisons: A/B, A/C.
re mean  SD unless indicated otherwise.
isorder; MDQ, Mood Disorder Questionnaire.
on.
were also provided.
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Weighted frequencies and percentages were also calculated and
represent the current study’s prevalence estimates for the Brazi-
lian population at large (see Fig. 1). Prevalence estimates were
further divided by gender. Of the Brazilian population 18 years of
age and older (N ¼ 137.9 million), 109.8 million (82.8%) individuals
were estimated to test negative for depressive symptoms, includ-
ing MDD. About 22.8 million (17.2%) were estimated to exhibit
symptoms consistent with MDD, of whom 13.5 million (59.3%)
were estimated to be MDD positive and 9.3 million (40.7%) were
negative. Of those who were MDD positive, the majority, 7.8
million (57.6%), were estimated to be unaware of their depression
(did not report experiencing depression in the past 12 months);
only 5.7 million (42.4%) were aware of their symptoms. Among
those who were estimated to be aware of their symptoms, a
substantial minority, 1.9 million (34.1%), was not diagnosed by a
physician; 3.8 million (65.9%) were estimated to be diagnosed.
Among those who were diagnosed with depression, a little more
than half, 2.1 million (54.5%), currently took a prescription
medication for their depression, while a little less than half, 1.7
million (45.5%), did not. Among those taking a prescription for
their depression, prevalence increased with severity, with nearly
six times the number of severely affected respondents, 1.2
million (59.6%), as moderately affected, 210,000 (10.2%) (see
Fig. 1 for details). A similar trend was observed for pharmaceu-
tically untreated respondents.
It is noteworthy that among respondents experiencing MDD,
men were less often aware of their depression than women
(30.9% men reporting depression vs. 46.6% not reporting), and
among those aware of their depression, men were less often
diagnosed (24.7% men diagnosed vs. 43.0% undiagnosed).
Respondent Demographic and Health Status Differences
In looking at the demographic characteristics of adults in Brazil,
compared with the nondepressed control group (98.7 million, n ¼
8,684), MDD treated patients and those untreated were more
likely to be women (71.5% and 79.9%, respectively, vs. 48.0% for
the control group). The youngest group consisted of untreated
MDD patients (mean age ¼ 35.8 years). Adults treated and those
untreated were more likely than the nondepressed controls to be
separated (14.0% and 12.3%, respectively, compared with 5.3%).
Levels of college education did not vary across the groups, nor did
household income or employment status (Table 1).
In terms of socioeconomic status, those untreated were more
likely to fall into the C1 socioeconomic group 4 (32.9%) than the
nondepressed control group (20.8%). In looking at regional dis-
tribution, those currently treated were more likely to be in the
south (30.4%) relative to those untreated and the nondepressed
control group (Table 1).
In comparing health habits and body mass index across the
groups, adults not treated were the most likely to drink alcohol
(67.8%), although treated patients were more likely than the
nondepressed group to smoke (38.0%). Mean body mass index
scores did not vary across the groups, but there were more obese
respondents in the treated (25.7%) and untreated (26.7%) groups.
Comorbid burden was higher among those treated and untreated
(Charlson scores ¼ 0.8 and 0.7, respectively) than among controls
(0.3) (Table 2).
Health Outcomes Differences
With respect to work-related impairment and activity impairment
(based on the WPAI questionnaire), adults treated for depression
were significantly more likely to have experienced absenteeism in
the past week relative to the nondepressed control group (36.6%
vs. 5.5%), and more hours of work missed (18.4 vs. 2.7 hours).Treated patients and untreated patients were more likely than the
nondepressed control group to have presenteeism (35.2% and
37.5%, vs. 11.2% for controls), overall work impairment (56.7%
and 43.0%, vs. 14.8%), and activity impairment (62.9% and 47.5%,
vs. 15.3%) (Table 3). In looking at the WPAI questionnaire scores
across the prescription users by severity, although not significant,
those with moderately severe and severe depression tended to
have higher percentage impairment scores for total work impair-
ment and activity impairment. Across those not using prescrip-
tion by severity, those with severe versus moderately severe
depression had the highest activity impairment (Table 4).
SF-12v2 scores were significantly lower for those treated and
untreated for depression relative to the nondepressed control group.
Treated patients had an average mental QOL score of 29.9, and
untreated patients had an average score of 29.5, relative to 50.4 for
controls (Po 0.05). Similarly, physical QOL scores were far below the
norm: treated patients had a mean score of 43.6 and untreated
scored 45.8, while controls scored 50.5 (Po 0.05) (Table 3). Average
QOL scores had a pattern of decreasing with increasing severity,
although most differences were not significant (Table 4).
Virtually all patients had seen a health care provider in the
past 6 months, with treated and untreated patients averaging
more visits than the nondepressed control group. In addition,
those treated with prescription and nontreaters alike were more
likely than the nondepressed control group to have been to the
ER, hospitalized, and to have visited any traditional health care
provider in the past 6 months (Table 3). The percentages of
patients visiting the ER in the past 6 months were highest for
the severe patients among the treated (Table 4).
With respect to depression condition characteristics, those
currently using a prescription were more likely to report depres-
sive symptoms that prompted discussion with a physician than
those not using prescription, along with symptoms such as the
following: Depressed mood and other emotional problems (e.g., hope-
lessness, tiredness, and anxiety) (P o 0.05) Sleep pattern changes (e.g., difficulty sleeping, oversleeping,
and waking up early) (P o 0.05)
In addition, adults currently being treated with prescription
were more likely than those not being treated with prescription
to be diagnosed by a psychiatrist (65.1% vs. 29.1%), and to classify
themselves as being ‘‘moderate’’ or ‘‘severe’’ versus ‘‘mild.’’ About
one third (31.6%) of treated patients were very/extremely satisfied
with their prescription therapy for their depression. Those not
treated with prescription were more likely than those who were
treated to rely on alternative therapies to manage depression
(Table 5).Conclusions
Among the projected 13.5 million Brazilian adults estimated to
test positive for MDD in the current study, 7.8 million (57.6%)
would not self-report experiencing depression, an additional 1.9
million (14.5%) would not report having been diagnosed with
depression, and another 1.7 million (12.7%) would not treat their
depression with prescription medication. In other words, only 2.1
million (15.3%) of the adults with MDD would report having been
diagnosed and treated for their condition.
The prevalence of MDD in the current study (10.2%) was
similar to 1-year prevalence estimates reported in recent studies
(7.1%–10.0%) [4–6]. In the S ~ao Paulo area, the prevalence of 9.6%
matched closely the 9.4% figure found in the S ~ao Paulo Megacity
Mental Health Survey [5]. We estimate that pharmacotherapy use
among MDD-positive individuals in Brazil (15.6%) is less than half
Table 4 – Health outcomes by MDD severity.
Among MDD, diagnosed with depression
Treated: Moderate
D,
Treated:
Moderately
severe E,
Treated: Severe
F,
Untreated: Moderate
G,
Untreated:
Moderately
severe H,
Untreated: severe
I,
210 K (n ¼ 29) 620 K (n ¼ 67) 1.2 M (n ¼ 88) 158 K (n ¼ 16) 601 K (n ¼ 63) 959 K (n ¼ 76)
Work productivity
% of missed work time (absenteeism)† 18.8  31.7 11.6  21.5 48.9  47.6 8.7  12.1 15.9  27.8 10.8  20.0
Hours missed (absenteeism)† 5.9  9.3 5.9  14.8 24.8  25.7 5.2  8.0 7.5  13.3 5.2  12.3
% of impairment at work
(presenteeism)†
29.0  26.3 47.5  33.9 27.2  33.5 49.5  27.8 26.5  25.4 40.6  30.4
% of overall impairment† 39.7  36.4 51.1  36.1 60.9  43.5 54.6  25.7 36.6  33.1 43.1  32.6
% of activity impairmentz 51.3  32.6 61.1  32.4 65.8  32.8 44.2  26.9 36.2  28.9 55.0  35.4H
Health-related quality of life
Mental component summary (MCS)
score
35.1  10.8 30.2  9.7 28.8  12.4 35.0  5.2 33.8  6.9I 25.9  10.0
Physical component summary (PCS)
score
45.7  8.6 47.0  9.8 41.5  11.0 46.8  7.5 49.7  8.2I 43.3  7.9
Health utilities 0.591  0.1F 0.557  0.1 0.534  0.1 0.579  0.1 0.621  0.1I 0.540  0.1
Resource use
Traditional health care provider visits
(including 0)
11.0  14.1 12.1  13.9 16.2  23.9 6.9  8.6 7.7  9.4 9.0  11.4
Median traditional health care
provider
visitsy
4.0 5.0 6.0 4.0 5.0 5.0
ER visits (including 0) 0.5  0.7 1.0  1.9 2.5  4.4 2.7  8.0 1.6  3.7 1.5  2.0
ER in past 6 mo, % (n) 40.1 (84 K) 34.1 (212 K) 65.7 (807 K)E 28.2 (45 K) 37.7 (226 K) 49.2 (472 K)
Hospitalized in past 6 mo, % (n) 16.4 (34 K) 10.9 (68 K) 31.5 (387 K) 7.8 (12 K) 16.5 (99 K) 20.1 (193 K)
Notes. Nondepressed control group: No depression symptoms, no bipolar disorder, and no positive MDQ score. Letters indicate the subgroup column(s) that differ significantly at Po 0.05.
Statistical comparisons noted on this table include the following column comparisons: D/E/F, G/H/I. Table includes results based on weighted and projected values.
ER, emergency room; K, thousand; M, million; MDD, major depressive disorder; MDQ, Mood Disorder Questionnaire.
* Patients who were treated for depression with a prescription medication.
† Employed full time.
z All respondents.
y Because of high values of visits for select respondents, median values were also provided.
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Table 5 – Depression questions.
Among MDD, diagnosed with depression: Use Rx for depression
Treated B, Untreated C,
2.1 M (n ¼ 184) 1.7 M (n ¼ 155)
% n % n
Self-reported depression severity
Mild 10.0 207 K 25.8B 443 K
Moderate 58.5 1.2 M 51.9 892 K
Severe 31.5 648 K 22.3 384 K
Alternative therapies: % using functional foods,
medications purchased not using a medical
prescription, popular medicine, and/or herbal products
37.6 774 K 44.6 767 K
Overall depression prescription medication satisfaction
(% very/extremely satisfied, 6–7 on a seven-point scale)
31.6 (not applicable)
Main symptoms that prompted seeing a doctor
Depressed mood and other emotional problems 91.5C 1.9 M 60.6 1.0 M
Eating pattern changes 37.9 780 K 25.5 438 K
Sleep pattern changes 65.2C 1.3 M 40.4 693 K
Mental changes 31.5 649 K 17.5 300 K
Social problems 26.5 546 K 23.2 399 K
Physical problems 19.4 398 K 17.5 301 K
None of the above – 0 K 0.7 13 K
No answer – 0 K 30.0 515 K
Clinician who diagnosed depression
Primary care physician/GP/internist 18.2 361 K 30.6 368 K
Psychiatrist 65.1C 1.3 M 29.1 349 K
Psychologist 10.5 207 K 23.3 281 K
Other 6.2 122 K 17.0 204 K
Notes. Nondepressed control group: No depression symptoms, no bipolar disorder, and no positive MDQ score. Letters indicate the subgroup
column(s) that differ significantly at Po 0.05. Statistical comparisons noted on this table include the following column comparisons: B/C.
Table includes results based on weighted and projected values.GP, general practitioner; K, thousand; M, million; MDQ, Mood Disorder Questionnaire.
* Patients who were treated for depression with a prescription medication.
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literature, we found that individuals with MDD were more likely
to be severely affected than moderately so, whether they were
treated or untreated with medications [5]. While the current
results agree with previous data suggesting that women are more
likely to be affected than men [4,6], other data show no gender
differences in prevalence [5]. We found no significant difference
in the mean age of individuals with MDD versus those without
MDD. Vorcaro et al. [6] found increased prevalence with age,
while Andrade et al. [4,5] found the opposite trend. Our results,
however, suggest that those with pharmaceutically treated MDD
tend to be older than those untreated.
Consistent with what others have reported [4–6], we found
individuals with MDD less likely to be employed than those
without MDD. Our study makes a novel contribution by extending
these analyses to work impairment. Indeed, respondents with
MDD reported substantially and significantly greater overall work
loss from absenteeism and presenteeism than did respondents
without MDD. Moreover, among those with pharmaceutically
treated MDD, work losses were greatest for those with severe
MDD. Similar results were found for health status and utility,
which worsened with MDD severity among pharmaceutically
treated and untreated individuals. As discussed in the Introduc-
tion, previous studies describing QOL or health status in indivi-
duals with MDD tend to employ special subsamples, such as
caretakers, health service workers, individuals with seriouscomorbidities, or the elderly, or were based in primary care
settings. Because SF-12v2 component summary scores are often
normalized to a mean of 50 (SD ¼ 10) for the general population,
it is illustrative to note that individuals without MDD in our
sample have similar scores (mental component summary score ¼
50.4; physical component summary score ¼ 50.5), whereas scores
for individuals with MDD (both treated and untreated) were
substantially lower (see Table 3). Individuals with the most severe
MDD reported the lowest scores. Differences in health care
resource use were also observed. The mean number of reported
ER visits, traditional health care provider visits, and hospitaliza-
tions were significantly higher among individuals with MDD
(treated and untreated) relative to those without MDD. Interest-
ingly, nontreated patients with MDD showed a trend of greater
resource use with severity, whereas treated individuals with MDD
did not. Our results show comparable rates of health care use as
Andrade et al. [5], but substantially greater use than others [32].
Qualitatively, individuals treated versus untreated for MDD
appeared to have the worst health outcomes, but because of the
confounding of morbidity with the likelihood of seeking depression
treatment, direct statistical comparisons and their interpretation
were avoided. For example, treated versus untreated patients were
more likely to report depression-related symptoms prompting a
discussion with their physician, plus they reported their condition
as more severe. Less than one-in-three treated patients were very
satisfied or extremely satisfied with their medication.
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causal conclusions from cross-sectional data and correlations.
Measures were assessed over different retrospective time periods
(e.g., PHQ-9 for the prior 2-week period, the WPAI questionnaire
over the past 7 days, and MDD over the past year), and so there is
likely to be variance (over- and underestimation) in extrapolating
from some results over the entire year. Although the treated,
untreated, and control samples matched reasonably well across
several sociodemographic characteristics, the current study did not
control for possible confounds (such as notable differences in sex,
obesity, and comorbidities); therefore, differences in health out-
comes across groups may be due to other factors besides depres-
sion. Future studies should control for these and other factors not
within the scope of the current study. Small subsamples across
severity groups may have obscured meaningful differences in
health outcomes because of limited power, as well as lack of
variance across groups that were already severe by default (i.e., all
had PHQ-9 total scores of at least 10). Future studies with larger
samples can allow for a more focused analysis of severity groups.
Furthermore, future studies utilizing more thorough sampling
techniques may help correct for any nonresponder selection biases
that potentially limit the generalizability of results from the current
study (e.g., lack of access to bedridden or terminally ill patients).
Overall, the current findings suggest that Brazilians may be
undertreated for MDD. Moreover, individuals with MDD reported
substantially lower health status, and greater work loss and health
care utilization, than did those without MDD. The most severely
affected individuals consistently reported the worst health outcomes.
Education campaigns informing Brazilians, especially males, about
MDD and the potential for symptom amelioration may improve
health outcomes among affected individuals. Further research is
needed to calculate the total economic impact of MDD in Brazil.Acknowledgment
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